Lawmakers and medical cannabis advocates gathered at Mercer University in Macon to explore broadening Georgia's decade-old medical cannabis program. The meeting highlighted calls for higher THC limits amid concerns that current restrictions limit patient access. With only three production facilities serving 33,000 approved patients through over 10 dispensaries, participants stressed the need for careful policy evolution.
Origins of Georgia's Restrictive Framework
Georgia legalized medical cannabis in 2015 as a low-THC oil program, designed to provide relief without psychoactive effects. This approach addressed patient needs for conditions like epilepsy while navigating federal prohibitions that long stifled research. Representative Mark Newton emphasized the study committee's role in deliberate review, avoiding hasty changes after nearly ten years of operation.
Evidence of Benefits Meets Slow Progress
Representative Robert Dickey pointed to observed advantages for patients in need, yet noted minimal medical research due to past federal illegality. The program's structure supports low-THC products only, contrasting with broader access in other states. Fine Fettle, one of three operating production facilities in Macon, serves as a key supplier but operates under potency caps that advocates argue fall short.
Push for THC Increases and Competitive Parity
Judson Hill, president of Fine Fettle, urged lawmakers to raise THC percentages, warning that Georgia lags behind 40 states with established medical cannabis regimes. Current limits hinder product strength and variety essential for certain patients. Expansion could align Georgia with national trends, potentially easing access while the study committee assesses risks and efficacy.
Implications for Patient Access Nationwide
Georgia's framework reflects broader tensions between caution and compassion in cannabis policy. Federal barriers have slowed scientific validation, leaving states to balance anecdotal benefits against unknowns. As discussions advance, outcomes may influence production capacity and patient enrollment, positioning Georgia to catch up or reinforce its conservative stance.
